Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

Jamie Kelter Davis / Bloomberg via Getty Images AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two ...

“Both Skyrizi and Rinvoq together are already capturing roughly one-third of the UC in-play market, which supports robust momentum going forward for both AbbVie brands.” “We are very pleased ...

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...

Gifting allows recipients to access the article for free. AbbVie Inc. rose the most in just over four years after it forecast 2025 earnings above Wall Street’s average expectation as two key ...

AbbVie expects full-year earnings in the range of $12.12 to $12.32 per share. AbbVie shares have fallen 1% since the beginning of the year, while the S&P’s 500 index has increased 27%. The stock ...

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline ...

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship ...